January 5, 2007

Cambrex Shareholders Approve Sale of Bio Business

Contact Cambrex

Stephanie LaFiura, Investor Relations Associate
+1 201.804.3037

EAST RUTHERFORD, NJ - Cambrex Corporation (NYSE: CBM, "Cambrex") today announced that at a Special Meeting of Shareholders held earlier today, its shareholders approved the sale of the Bioproducts and Biopharma subsidiaries (the "Bio Businesses") to Lonza Group AG ("Lonza").

James A. Mack, Chairman, President and Chief Executive Officer of Cambrex Corporation, said: "We are pleased that our shareholders overwhelmingly support the sale of our Bio Businesses to Lonza. We feel that this transaction represents the most compelling means for realizing value for Cambrex shareholders."

Cambrex and Lonza anticipate closing this transaction within the next two to five business days.